Pharma channel feed

Pfiz­er plans to pull out of BIO, fol­low­ing moves by oth­er large drug­mak­ers to re­duce lob­by­ing foot­print

Last year
FDA+

FDA ap­proves No­var­tis drug for rare blood dis­or­der

Last year
FDA+

Up­dat­ed: Will the UK’s triple-pronged ap­proach ease pric­ing, reg­u­la­to­ry and fi­nan­cial bot­tle­necks?

Last year
In Focus

J&J note­book: High­lights from a day of pipeline and strat­e­gy dis­cus­sion

Last year
R&D

FDA sends let­ter to No­var­tis over Kym­ri­ah man­u­fac­tur­ing safe­ty con­cerns

Last year
FDA+
Manufacturing

The pol­i­tics be­hind drug short­ages: Sen­a­tors talk is­sues with gener­ics mar­ket, CMS pay­ments

Last year
FDA+

Sen. Bill Cas­sidy plots a path for more com­mer­cial­ly vi­able cell and gene ther­a­pies

Last year
Cell/Gene Tx

As­traZeneca says CMS guid­ance around IRA ex­emp­tions is 'un­law­ful' in lat­est court brief

Last year
Law

Mar­ket­ingRx roundup: Phar­mas dou­ble down on re­new­able en­er­gy; Bay­er funds health eq­ui­ty re­search

Last year
Marketing

Obe­si­ty deals come in­to fo­cus af­ter Roche shells out $2.7B for Car­mot

Last year
Deals

Bausch Health’s Sal­ix ini­ti­ates first aware­ness day for opi­oid-in­duced con­sti­pa­tion

Last year
Marketing

Boehringer looks 'be­yond sta­ble' to dis­play the every­day re­al­i­ties of life with schiz­o­phre­nia

Last year
Marketing

J&J promis­es 20 new drugs to back phar­ma growth through end of decade, as John Reed shares his plans

Last year
R&D

Roche's BTK in­hibitor put on par­tial hold over con­cerns about po­ten­tial liv­er in­jury

Last year
FDA+

Fu­ji­film makes $200M man­u­fac­tur­ing in­vest­ment while No­var­tis pours $80M+ in­to Chi­na fa­cil­i­ty

Last year
Manufacturing

House com­mit­tee in­ves­ti­gates FDA’s han­dling of com­mon nasal de­con­ges­tant as ef­fi­ca­cy ques­tions loom

Last year
FDA+

No­var­tis un­veils new brand iden­ti­ty af­ter San­doz spin­off

Last year
Marketing

FDA ap­proves Lil­ly’s BTK in­hibitor Jaypir­ca for two more blood can­cers

Last year
FDA+

Sam­sung Bioepis strikes deal for Ste­lara biosim­i­lar, but launch like­ly won't come in time for an IRA ex­emp­tion

Last year
FDA+

EMA sends more ques­tions to GLP-1 mak­ers over pos­si­ble risk of sui­cide, self-harm

Last year

No­var­tis taps ‘So­pra­nos’ ac­tress for new mul­ti­ple scle­ro­sis Kes­imp­ta cam­paign

Last year
Marketing

Ot­su­ka am­pli­fies re­search-based men­tal health pro­gram, adds first dig­i­tal ac­cess

Last year
Marketing

As­traZeneca halts two PhI­II hy­per­kalemia stud­ies in­tend­ed to spot­light Lokel­ma’s clin­i­cal val­ue

Last year

J&J ac­quires Cal­i­for­nia med­ical de­vice com­pa­ny for $400M

Last year
Deals
First page Previous page 86878889909192 Next page Last page
A service from the Financial Times